CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home Search
Result Type
Evidence Bundles
Product Line
Body Systems
Disease and Conditions
Target Population
Technologies, Therapies and Systems
Testing and Diagnostics
Publication Date
Clear all filters

Reports

We found 6362 result(s)

osimertinib (Tagrisso )

Last Updated: April 8, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: osimertinib
Indications: Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

  • Brand Name: Tagrisso
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: PC0246-000
  • Project Status: Active
  • Submission Type: Initial
Details

New at CADTH - April 2021

Last Updated: April 9, 2021
Result type: Reports
Product Line: New at CADTH

News and Events Call for Nominations Now Open for CADTH Board and Expert Committees
CADTH is seeking 15 new members from across the country for its Board of Directors and expert committees. Visit nominations.cadth.ca for details. The deadline to submit an application is Monday, April 26th, 2021. CADTH Recommends Gene Therapy fo...

dupilumab (Dupixent )

Last Updated: April 6, 2021 - March 2, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dupilumab
Indications: Dupixent (dupilumab injection) is indicated for the treatment of patients aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT® can be used with or without topical corticosteroids.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0682-000
  • Project Status: Pending
  • Submission Type: Initial
Details

encorafenib (Braftovi)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: encorafenib
Indications: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.

  • Brand Name: Braftovi
  • Manufacturer: Pfizer Canada ULC
  • Project Number: PC0233-000
  • Project Status: Active
  • Submission Type: Initial
Details

COVID-19 Update

Last Updated: April 6, 2021
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 Evidence Portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and increasing international scientific evidence related t...

natalizumab (Tysabri)

Last Updated: April 5, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: natalizumab
Indications: Tysabri (intravenous, IV; and subcutaneous, SC) is indicated as monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. Tysabri is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.

  • Brand Name: Tysabri
  • Manufacturer: Biogen Canada, Inc.
  • Project Number: SR0687-000
  • Project Status: Pending
  • Submission Type: Initial
Details

givosiran (Givlaari)

Last Updated: April 5, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: givosiran
Indications: ​Treatment of acute hepatic porphyria (AHP) in adults

  • Brand Name: Givlaari
  • Manufacturer: Alnylam Netherlands B.V.
  • Project Number: SR0679-000
  • Project Status: Active
  • Submission Type: Initial
Details

somatrogon (TBC)

Last Updated: April 5, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: somatrogon
Indications: ​Long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone.

  • Brand Name: TBC
  • Manufacturer: Pfizer Canada ULC
  • Project Number: SR0683-000
  • Project Status: Pending
  • Submission Type: Initial
Details